Document Detail


Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype.
MedLine Citation:
PMID:  9517378     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
1. In this study we investigated whether long-term trimetazidine (anti-ischaemic drug) therapy alters the ventricular myosin heavy chain (MHC) isoform composition in a model of cardiomyopathy. 2. MHC isoforms were analysed in the native state by electrophoresis in a pyrophosphate buffer. Myosin isoform patterns were studied in cardiac muscle from cardiomyopathic hamsters (CMH) of the BIO 14:6 strain during the time course of the disease and compared with those of healthy golden hamsters (F1B). The correlation between myosin profile and Ca2+-activated ATPase activity was determined from 220 days. 3. At the stage of insufficiency (350 days), CMH presented the most abnormal phenotype with 53% V1-24% V3 compared to 79% V1-7% V3 (P<0.001), in F1B. Trimetazidine was administered to cardiomyopathic hamsters from the early stage of active disease (30 days) to the congestive stages (220-350 days). Within 65 days, trimetazidine treatment, in CMH and F1B, reduced V1 to a low level (53% and 62%, respectively), which remained constant throughout the treatment. This level was similar to that in 220 and 350 days-old untreated-CMH. In sharp contrast, a standard calcium blocker, verapamil, administered to CMH in the same conditions resulted in a higher V1 (about 70%) and higher global myosin ATPase activity from 220 days. 4. Previous results in terms of hypertrophy and survival, compared to these results, suggest that verapamil and trimetazidine treatments reveal a dissociation between ventricular hypertrophy and isomyosin distribution. In addition, the shift in favour of V3 may not necessarily be an aggravating factor of the disease but an adaptative compensatory event.
Authors:
N D'hahan; K Taouil; C Janmot; J E Morel
Related Documents :
15368798 - Recent insights in the development of organ damage caused by hypertension.
15170858 - Nitric oxide and the enigma of cardiac hypertrophy.
20643208 - Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters ...
8184288 - Valve replacement for aortic stenosis: the curative potential of early operation.
12174028 - Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angioten...
7178228 - Interaction of ouabain and propranolol in the central nervous system. neurally-mediated...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  123     ISSN:  0007-1188     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-04-16     Completed Date:  1998-04-16     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  611-6     Citation Subset:  IM    
Affiliation:
Laboratoire de Biologie, Ecole Centrale Paris, Châtenay-Malabry, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Calcium Channel Blockers / therapeutic use*
Calcium-Transporting ATPases / metabolism
Cardiomyopathies / drug therapy*,  enzymology,  genetics
Cricetinae
Electrophoresis, Polyacrylamide Gel
Mesocricetus
Myosins / genetics*,  isolation & purification
Phenotype
Trimetazidine / therapeutic use*
Vasodilator Agents / therapeutic use*
Verapamil / therapeutic use*
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Vasodilator Agents; 5011-34-7/Trimetazidine; 52-53-9/Verapamil; EC 3.6.1.8/Calcium-Transporting ATPases; EC 3.6.4.1/Myosins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ipriflavone as an inhibitor of human cytochrome P450 enzymes.
Next Document:  Mediators and mechanisms of relaxation in rabbit urethral smooth muscle.